Board of Directors

 

Rupert Lywood, Chairman

Rupert is a Chartered Accountant who qualified with Robson Rhodes. Latterly he specialised in structured finance and venture capital. Rupert has spent the last 25 years founding and building businesses in the energy, information, finance, medical, and media sectors – including co-founding and chairing a multi-billion European energy business which he sold to International Power in 2007. He remains active in all these sectors and in addition is currently focused on creating and delivering literacy programs in both the Developed and Developing World.

 

Paul Weinberger, Chief Executive Officer

Paul joined Origin in 2015, bringing 25 years of expertise in the IVD, Medical Device and Pharmaceutical industries. He has extensive experience of starting and growing companies, having founded Diasolve Ltd and Guidewave Ltd, and worked as CMO for Lumora Ltd (now ERBA MDX) and Director of Clinical Development at Enigma Diagnostics where he led the early development of the ML PCR system. Earlier experience included 10 years with Roche Diagnostics and five with The Wellcome Foundation (now GSK).

In other business related activities Paul has spent six years as a founding member of the NICE Diagnostics Advisory Committee, and is currently a member of the BIVDA board. He has an MBA from London Business School and a first degree in pharmacology.

 

Graham Griffiths, Commercial Director

Graham has a background in law, investment, product development, and the commercialisation of new technologies. He qualified as a solicitor, before founding a services company that was successfully sold to private investors in 2009. Graham secures investment and re-investment in Life Science companies, and identifies, negotiates and manages strategic alliances. Graham also serves on the board of Agalimmune Ltd, which is developing a clinical stage cancer immunotherapy for solid tumours.

 

Stuart Lawson, Finance Director

Stuart is CEO of the private investment group headed by Animatrix Capital LLP, which holds a broad range of investments with the core focus being early stage medical research. Stuart serves as CFO of group members Loxbridge Research LLP, Premaitha Health Ltd and Agalimmune Ltd. He qualified as a Chartered Accountant before working as a Manager at KPMG. He then worked as a Finance Director before moving to and becoming Group CFO and European MD with a LSE fully quoted manufacturing company; during his time he led them through 16 Global acquisitions. Stuart is also a Trustee for the children’s charity, The Safepoint Trust, and serves as Chairman of a Mergers & Acquisitions Company based in Istanbul.

 

Per Aniansson, Director

Per Aniansson is currently an Investment Director at Fouriertransform AB, a Swedish Venture Capital/Private Equity company. He holds an MSc Engineering Physics from Chalmers University of Technology and an MBA from INSEAD. Prior to joining Fouriertransform Mr Aniansson gained experience in venture capital investments and other major investments from positions with Industrivärden, Siemens and Innovationskapital. Mr Aniansson was also a Management consultant with Accenture and Arthur D Little, mainly with a focus in the Pharma and Medtech business. He is on the board of a number of technology companies of which two are in the UK, Origin Sciences Ltd and Star Syringe Ltd.